John F. Seymour
Peter MacCallum Cancer Centre
781 Papers
5.1K Citations
John F. Seymour is an academic researcher from Peter MacCallum Cancer Centre. The author has contributed to research in topics: Medicine & Rituximab. The author has an hindex of 96, co-authored 706 publications. Previous affiliations of John F. Seymour include Royal Children's Hospital & St. Vincent's Health System.
Chat about Author
Papers
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION
Adrian G. Minson,Emma Verner,Pratyush Giri,Shu Min Wong,Sumita Ratnasingam,Jason Butler,Wojciech Janowski,Matthew Ku,Chan Yoon Cheah,Mark Hertzberg,K. Herbert,Nada Hamad,Costas K Yannakou,Paul J Neeson,Javad Saghebi,Piers Blombery,Molly Robertson,Lai-Shan Lau,John F. Seymour,Michael Dickinson +19 more
2
Pulmonary Hypertension (PHT) and Pleural Effusion During Dasatinib Therapy For CML Frequently Lead To Drug Withdrawal
TL;DR: It is found clinically relevant pulmonary complications of DAS therapy to be more frequent than previously reported, perhaps due to non-specific symptoms and low levels of awareness.
2
The Frequency, Manifestations and Duration of Prolonged Cytopenias after First Line Fludarabine-Combination Chemotherapy for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Saar Gill,Dennis A. Carney,David Ritchie,Max Wolf,David Westerman,H. Miles Prince,Henry Januszewicz,John F. Seymour +7 more
TL;DR: Evaluated patients with indolent non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with fludarabine with or without other agents as their first-line cytotoxic therapy found no evidence of post-treatment cytopenias.
2
Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Rachael A Ralli,Kellie-Marie Banks,Adrian Wiegmans,Dennis A. Carney,John F. Seymour,John F. Seymour,Ricky W. Johnstone,Ricky W. Johnstone,A E Alsop +8 more
TL;DR: Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
2